A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. Effect of extended treatment with IAP inhibitor xevinapant post radiotherapy (RT ...
HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib minor resection study ...
Exploring the combination with atezolizumab and radiation therapy Study led by Yale University MADRID, Spain and CAMBRIDGE, Mass., Feb. 09, 2026 ...
Phase Ib study of open-label AMG 386 plus paclitaxel (P) and trastuzumab (T) or capecitabine (C) and lapatinib (L) in patients (pts) with HER2+ locally recurrent or metastatic breast cancer (MBC).
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage ...
The trial is conducted at the Mays Cancer Center, part of the University of Texas at San Antonio’s Health Science Center.
(RTTNews) - Ascletis Pharma Inc. (ASCLF.PK) announced positive topline results from its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30 oral ...
The MERS coronavirus—MERS stands for “Middle East Respiratory Syndrome”—causes severe respiratory diseases with a high mortality rate. To date, there is neither a vaccine nor a specific treatment. The ...